-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Unicycive Therapeutics, Inc. (NASDAQ:UNCY) Sees Significant Growth in Short Interest
Unicycive Therapeutics, Inc. (NASDAQ:UNCY) Sees Significant Growth in Short Interest
Unicycive Therapeutics, Inc. (NASDAQ:UNCY – Get Rating) was the recipient of a large increase in short interest in the month of December. As of December 30th, there was short interest totalling 259,000 shares, an increase of 284.3% from the December 15th total of 67,400 shares. Approximately 2.9% of the company's shares are sold short. Based on an average trading volume of 243,700 shares, the days-to-cover ratio is currently 1.1 days.
Unicycive Therapeutics Price Performance
Shares of UNCY traded down $0.00 during trading hours on Thursday, hitting $0.53. 62,326 shares of the stock were exchanged, compared to its average volume of 211,827. The firm has a market capitalization of $7.98 million, a P/E ratio of -0.52 and a beta of 1.35. The business has a 50-day moving average of $0.64 and a 200-day moving average of $0.69. Unicycive Therapeutics has a fifty-two week low of $0.40 and a fifty-two week high of $2.08.
Get Unicycive Therapeutics alerts:Unicycive Therapeutics (NASDAQ:UNCY – Get Rating) last posted its quarterly earnings results on Monday, November 14th. The company reported ($0.37) EPS for the quarter, missing analysts' consensus estimates of ($0.35) by ($0.02). The business had revenue of $0.95 million for the quarter. As a group, analysts forecast that Unicycive Therapeutics will post -1.13 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Unicycive Therapeutics
An institutional investor recently raised its position in Unicycive Therapeutics stock. Nantahala Capital Management LLC boosted its stake in Unicycive Therapeutics, Inc. (NASDAQ:UNCY – Get Rating) by 13.9% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 729,680 shares of the company's stock after purchasing an additional 89,047 shares during the quarter. Nantahala Capital Management LLC owned about 4.86% of Unicycive Therapeutics worth $606,000 as of its most recent SEC filing. 6.43% of the stock is owned by institutional investors and hedge funds.Analyst Ratings Changes
Separately, HC Wainwright decreased their price target on shares of Unicycive Therapeutics from $9.00 to $8.00 and set a "buy" rating for the company in a research report on Monday, November 28th.
Unicycive Therapeutics Company Profile
(Get Rating)
Unicycive Therapeutics, Inc, a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease; and UNI 494, for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.
See Also
- Get a free copy of the StockNews.com research report on Unicycive Therapeutics (UNCY)
- High-Dividend-Yielding BHP Sees China Driving '23 Growth
- Is Airbnb Setting Up To Rally 38%, As Analysts Are Forecasting?
- Does a Price Cut for Tesla Vehicles Mean the Same for TSLA Stock?
- Microsoft Layoffs Signal Layoffs for Other Tech Companies?
- More Than One Reason To Buy Fastenal, Quickly
Receive News & Ratings for Unicycive Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Unicycive Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
纳斯达克公司(纳斯达克代码:UNCY-GET评级)是12月份空头股数价格大幅增长的接受者。截至12月30日,空头股数共有259,000股,比12月15日的67,400股增加了284.3%。该公司约2.9%的股票被卖空。以平均成交量243,700股计算,目前天数与回补比率为1.1天。
单周期治疗药物的价格表现
在周四的交易时间里,Uncy的股价下跌了0.00美元,达到0.53美元。该股成交量为62,326股,而平均成交量为211,827股。该公司的市值为798万美元,市盈率为-0.52,贝塔系数为1.35。该业务的50日移动均线切入位在0.64美元,200日移动均线切入位在0.69美元。Unicycive Treateutics的股价为0.40美元,为52周低点,52周高点为2.08美元。
到达单周期治疗学警报:优尼赛夫治疗公司(纳斯达克:UNCY-GET评级)上一次公布季度收益是在11月14日星期一。该公司公布了该季度每股收益(0.37美元),低于分析师普遍预期的(0.35美元)和(0.02美元)。该业务本季度的收入为95万美元。分析师预测,Unicycive Treateutics作为一个集团,本财年每股收益将达到1.13美元。
机构投资者看好Uncycive Treeutics
一家机构投资者最近提高了对Unicycive Treateutics股票的头寸。根据Nantahala Capital Management LLC提交给美国证券交易委员会的最新Form 13F文件,该公司在第二季度将其在Uncycive Treateutics,Inc.(纳斯达克:UNCY-GET评级)的股份增持了13.9%。该公司在本季度额外购买了89,047股后,持有该公司729,680股股票。截至最近提交给美国证券交易委员会的文件,Nantahala Capital Management LLC拥有Uncycive Treateutics约4.86%的股份,价值606,000美元。6.43%的股票由机构投资者和对冲基金持有。分析师评级发生变化
另外,HC Wainwright在11月28日(星期一)的一份研究报告中将Unicycive Treeutics的股票目标价从9.00美元下调至8.00美元,并为该公司设定了“买入”评级。
Uncycive治疗公司简介
(获取评级)
Unicycive Treateutics,Inc.是一家生物技术公司,在美国致力于开发肾脏疾病的新疗法。它正在开发Renazorb,用于治疗慢性肾脏疾病患者的高磷血症;以及UNI 494,用于治疗急性肾脏损伤。该公司成立于2016年,总部设在加利福尼亚州洛斯阿尔托斯。
另请参阅
- 免费获取StockNews.com关于单周期免疫疗法(UNCY)的研究报告
- 高股息率的必和必拓认为中国推动了23年的增长
- 爱彼迎的涨幅是否会像分析师预测的那样达到38%?
- 特斯拉汽车降价是否意味着特斯拉股票也会降价?
- 微软的裁员标志着其他科技公司的裁员?
- 快速购买Fastenal的原因不止一个
接受《单细胞治疗日报》的新闻和评级-在下面输入您的电子邮件地址,即可通过MarketBeat.com的免费每日电子邮件时事通讯接收对Unicycive治疗公司和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧